GLAXO.NS Balance Sheet
Glaxosmithkline Pharmaceuticals Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-24 01:36
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹294.81 Cr. | ₹296.80 Cr. | ₹269.54 Cr. | ₹273.51 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹20.31 Cr. | ₹13.93 Cr. | ₹14.32 Cr. | ₹32.93 Cr. | CapitalWorkInProgress |
| Goodwill | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | Goodwill |
| Other Intangible Assets | ₹34.09 Cr. | ₹23.55 Cr. | ₹13.33 Cr. | ₹6.56 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹52.43 Cr. | ₹52.83 Cr. | ₹51.85 Cr. | ₹77.34 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹618.36 Cr. | ₹544.56 Cr. | ₹502.19 Cr. | ₹539.16 Cr. | NoncurrentAssets |
| Inventories | ₹459.97 Cr. | ₹525.05 Cr. | ₹481.74 Cr. | ₹457.55 Cr. | Inventories |
| Trade Receivables | ₹192.38 Cr. | ₹222.06 Cr. | ₹292.55 Cr. | ₹273.11 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹34.94 Cr. | ₹64.17 Cr. | ₹538.85 Cr. | ₹1,102.05 Cr. | CashAndCashEquivalents |
| Current Investments | ₹518.29 Cr. | ₹813.22 Cr. | ₹1,118.25 Cr. | ₹1,390.96 Cr. | CurrentInvestments |
| Other Current Assets | ₹30.04 Cr. | ₹44.73 Cr. | ₹43.05 Cr. | ₹54.38 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹2,708.22 Cr. | ₹3,012.06 Cr. | ₹3,605.89 Cr. | ₹3,784.71 Cr. | CurrentAssets |
| Total Assets | ₹3,326.58 Cr. | ₹3,556.62 Cr. | ₹4,108.08 Cr. | ₹4,323.87 Cr. | Assets |
| Equity Share Capital | ₹169.41 Cr. | ₹169.41 Cr. | ₹169.41 Cr. | ₹169.41 Cr. | EquityShareCapital |
| Other Equity | ₹1,571.87 Cr. | ₹1,608.23 Cr. | ₹1,781.90 Cr. | ₹2,098.01 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹1,741.28 Cr. | ₹1,777.64 Cr. | ₹1,951.31 Cr. | ₹2,267.42 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹17.27 Cr. | NonControllingInterest |
| Total Equity | ₹1,741.28 Cr. | ₹1,777.64 Cr. | ₹1,951.31 Cr. | ₹2,284.69 Cr. | Equity |
| Long-term Borrowings | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹258.94 Cr. | ₹254.03 Cr. | ₹251.60 Cr. | ₹260.07 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | ₹0.00 Cr. | BorrowingsCurrent |
| Trade Payables | ₹427.79 Cr. | ₹625.41 Cr. | ₹708.26 Cr. | ₹570.22 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹56.20 Cr. | ₹53.13 Cr. | ₹71.50 Cr. | ₹118.18 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹1,326.36 Cr. | ₹1,524.95 Cr. | ₹1,905.17 Cr. | ₹1,779.11 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹3,326.58 Cr. | ₹3,556.62 Cr. | ₹4,108.08 Cr. | ₹4,323.87 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from GLAXO.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).